5HJ Stock Overview
A clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
enVVeno Medical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.14 |
| 52 Week High | US$6.05 |
| 52 Week Low | US$2.38 |
| Beta | 1.21 |
| 1 Month Change | 24.60% |
| 3 Month Change | 3.97% |
| 1 Year Change | -13.26% |
| 3 Year Change | -34.58% |
| 5 Year Change | n/a |
| Change since IPO | -60.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5HJ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 1.3% | 2.9% | 3.5% |
| 1Y | -13.3% | -5.0% | 13.1% |
Return vs Industry: 5HJ underperformed the German Medical Equipment industry which returned -4.9% over the past year.
Return vs Market: 5HJ underperformed the German Market which returned 12.8% over the past year.
Price Volatility
| 5HJ volatility | |
|---|---|
| 5HJ Average Weekly Movement | 10.3% |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5HJ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5HJ's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 31 | Robert Berman | www.envveno.com |
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company’s lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI.
enVVeno Medical Corporation Fundamentals Summary
| 5HJ fundamental statistics | |
|---|---|
| Market cap | €55.39m |
| Earnings (TTM) | -€20.39m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.7x
P/E RatioIs 5HJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5HJ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$21.24m |
| Earnings | -US$21.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.21 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 5HJ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 20:40 |
| End of Day Share Price | 2025/01/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
enVVeno Medical Corporation is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Cohen | Ladenburg Thalmann & Company |